Niagen Bioscience: A Great Company Suffering From Stock Dilution

Niagen Bioscience (NASDAQ:NAGE) posted strong Q2 earnings with positive cash flow and a debt-free balance sheet. Yet years of stock dilution weigh heavily on intrinsic value, with my DCF model estimating fair value at $4.04 per share. Despite product strength, I rate the stock a cautious hold.